#345 Dexcom CEO Returns

CGM Progress

Kevin Sayer, CEO of Dexcom, shares insights into the rapid advancements in continuous glucose monitoring (CGM) technology. He reflects on the journey from the G6 to the upcoming G7 model, emphasizing the importance of scaling production to meet demand and the ongoing improvements in integration and data utilization 1. Sayer notes, "We're still learning how good it is. We are learning the subtle things we can do to improve it" 1. The G6 has been pivotal in diabetes management, and while the G7's launch is delayed due to COVID-19, the focus remains on enhancing the current model's capabilities 2.

   

Partnerships

Dexcom's collaborative efforts with companies like Omnipod and Tandem are revolutionizing diabetes technology. Scott Benner highlights the success of these partnerships, noting the strong user interface and time-in-range data from systems like Tandem's Control-IQ 3. Sayer adds, "We're looking forward to another integrated system and more choice for our patients" 2. These collaborations are not only enhancing patient experience but also expanding the reach and effectiveness of CGM systems.

   

Global Growth

Dexcom is making significant strides in the European market, with new approvals enhancing its product offerings. Kevin Sayer discusses the importance of the back-of-the-arm indication and its relevance for pregnant patients, who often face space constraints for sensor placement 4. He shares a personal story, "I have twin grandbabies from a daughter-in-law who had gestational diabetes," highlighting the critical role of CGM in managing diabetes during pregnancy 4. These advancements underscore Dexcom's commitment to addressing diverse patient needs and expanding its global footprint.